Assessment of pharmacokinetic (PK) and pharmacodynamic (PD) interaction between warfarin and repaglinide

被引：0
|
作者：
Rosenberg, M
Strange, P
Cohen, A
机构：
来源：
DIABETES | 1999年 / 48卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
1559
引用
收藏
页码：A356 / A356
页数：1
相关论文
共 50 条
  • [31] Bioavailability assessment of disopyramide using pharmacokinetic-pharmacodynamic (PK-PD) modeling in the rat
    Miyazaki, M
    Maekawa, C
    Iwanaga, K
    Morimoto, K
    Kakemi, M
    BIOLOGICAL & PHARMACEUTICAL BULLETIN, 2000, 23 (11) : 1363 - 1369
  • [32] ASSESSMENT OF PHARMACOKINETIC INTERACTION BETWEEN PRADIGASTAT AND EFAVIRENZ OR REPAGLINIDE IN HEALTHY SUBJECTS.
    Kulmatycki, K. M.
    Meyers, D.
    Danis, K.
    Neelakantham, S.
    Su, Z.
    Majumdar, T.
    Sam, R.
    Sunkara, G.
    Chen, J.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2014, 95 : S48 - S49
  • [33] Assessment of the pharmacokinetic-pharmacodynamic interaction between terazosin and finasteride
    Samara, EE
    Hosmane, B
    Locke, C
    Eason, C
    Cavanaugh, J
    Granneman, GR
    JOURNAL OF CLINICAL PHARMACOLOGY, 1996, 36 (12): : 1169 - 1178
  • [34] LACK OF A PHARMACOKINETIC AND PHARMACODYNAMIC INTERACTION BETWEEN DIMEBON (LATREPIRDINE) AND WARFARIN IN HEALTHY SUBJECTS.
    Plowchalk, D. R.
    Qiu, R.
    Terra, S. G.
    Corrigan, B.
    Fang, J.
    Fullerton, T.
    Liu, J.
    Byon, W.
    Mordenti, J.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2010, 87 : S57 - S57
  • [35] Pharmacokinetic and pharmacodynamic study of the potential drug interaction between tasosartan and warfarin in healthy subjects
    Battle, MM
    Klamerus, KJ
    Neefe, DL
    Georgieff, IS
    Mayer, PR
    JOURNAL OF HYPERTENSION, 1998, 16 : S123 - S123
  • [36] Population Pharmacokinetic (PK) and Pharmacokinetic/Pharmacodynamic (PK/PD) Analyses to Support Olaparib Tablet Approval in Ovarian Cancer
    Xu, Hongmei
    Zhou, Diansong
    Li, Jianguo
    Berges, Alienor
    Bui, Khanh
    Milenkova, Tsveta
    Tomkinson, Helen
    Al-Huniti, Nidal
    Learoyd, Maria
    JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS, 2018, 45 : S36 - S36
  • [37] Evaluation of pharmacokinetic and pharmacodynamic interactions between eszopiclone and warfarin
    Maier, G
    Roach, J
    Rubens, R
    SLEEP, 2004, 27 : 56 - 56
  • [38] In vitro dynamic pharmacokinetic/pharmacodynamic(PK/PD) modeling and PK/PD cutoff of cefquinome against Haemophilus parasuis
    Xia Xiao
    Jian Sun
    Yi Chen
    Rui-Juan Huang
    Ting Huang
    Guilin Gary Qiao
    Yu-Feng Zhou
    Ya-Hong Liu
    BMC Veterinary Research, 11
  • [39] Pharmacokinetic/pharmacodynamic/(PK/PD) model for abciximab in healthy subjects.
    Abernethy, DR
    Pezzullo, J
    Freedman, J
    Mascelli, MA
    Frederick, B
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2000, 67 (02) : 141 - 141
  • [40] HYDROMORPHONE BIOAVAILABILITY AND PHARMACOKINETIC-PHARMACODYNAMIC (PK-PD) RELATIONSHIPS
    INTURRISI, C
    PORTENOY, R
    STILLMAN, M
    COLBURN, W
    FOLEY, K
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 1988, 43 (02) : 162 - 162
12345